After reintroduction, Tysabri builds patient base

A year after Tysabri was reintroduced for multiple sclerosis, its manufacturers say that 14,000 patients are now taking the drug. Tysabri, once viewed as a major breakthrough for MS, was pulled after the drug was linked to a risk of PML, a viral infection of the brain. Elan and Biogen Idec make the drug.

- read the report from Finfacts

Related Articles:
FDA allows Tysabri back on market. Report
FDA allows limited trial of Tysabri. Report
Tysabri may spur better risk/reward evaluation. Report
Elan hammered on reported case of PML. Report

Suggested Articles

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.